acalabrutinib

Overview

Acalabrutinib is a selective, covalent Bruton tyrosine kinase (BTK) inhibitor used as a targeted therapy in B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). By inhibiting BTK, a key signaling molecule in the B-cell receptor pathway, acalabrutinib reduces survival and proliferation signals in malignant B cells. It is generally described as a second-generation BTK inhibitor and is distinguished from earlier agents by its greater selectivity for BTK.

In the biomedical literature provided, acalabrutinib is presented as an approved therapy for CLL/SLL and as a comparator or backbone treatment in studies evaluating treatment-naive and relapsed/refractory disease. Related research also places it in the context of other targeted agents such as ibrutinib and the venetoclax, reflecting its role in modern combination and sequencing strategies for CLL.

Focus of Latest Publications

Recent publications centered on acalabrutinib primarily address its clinical effectiveness, safety, comparative performance, and rare adverse events in CLL.

A final phase 2 study reported results for acalabrutinib in both treatment-naive and relapsed/refractory CLL, reinforcing its established role as a selective, covalent BTK inhibitor approved for CLL/SLL. This study contributes to the evidence base supporting acalabrutinib as an active therapy across disease settings.

Real-world evidence was also highlighted in the EPIC study, which followed first-line acalabrutinib monotherapy for 3 years. The publication emphasized that while clinical trials have shown acalabrutinib to be safe and effective in CLL, real-world data remain important for understanding how the drug performs in routine practice. This study therefore extends the clinical picture beyond trial populations.

Combination and comparative research featured prominently as well. An indirect comparison examined zanubrutinib versus acalabrutinib plus venetoclax in treatment-naive CLL, and the cited sentence noted that acalabrutinib-venetoclax, with or without obinutuzumab, demonstrated prolonged progression-free survival versus chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab (FCR) or bendamustine-rituximab (BR) in patients without del(17p) or TP53 mutations. This places acalabrutinib in the context of fixed-duration or combination targeted therapy strategies alongside the venetoclax.

Economic evaluation also formed part of the recent literature. One study assessed the cost-effectiveness of ibrutinib, acalabrutinib, and zanubrutinib for CLL within South Africa’s public healthcare system. This indicates that acalabrutinib is being considered not only for clinical efficacy but also for health-system value relative to other BTK inhibitors.

Finally, a case report described acquired pseudo-Pelger-Huët anomaly in a patient with CLL treated with acalabrutinib. The report noted that an association between pseudo-Pelger-Huët anomaly and acalabrutinib had not previously been described, suggesting attention to uncommon hematologic findings during therapy. While this does not establish causality, it expands awareness of potential laboratory or morphologic abnormalities observed during treatment.

Key Publications

Jun Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. (Blood advances, 2026, PMID 41915892): "Acalabrutinib is a selective, covalent Bruton tyrosine kinase inhibitor approved for marketing in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)."
May Acquired Pseudo-Pelger-Huet anomaly in a patient with chronic lymphocytic leukemia treated with acalabrutinib. (Journal of hematopathology, 2026, PMID 42103972): "...an association of PPHA with acalabrutinib has not been previously described."
May Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. (Applied health economics and health policy, 2026, PMID 41739322): "This study evaluated the cost effectiveness of ibrutinib, acalabrutinib, and zanubrutinib for the treatment of CLL from the perspective of South Africa's public healthcare system."
May Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study. (Blood advances, 2026, PMID 42054544): "Clinical trials indicate that acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, is safe and effective for treating patients with chronic lymphocytic leukemia (CLL), but real-world evidence on its clinical effectiveness is limited."
Apr An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL. (Blood advances, 2026, PMID 41587482): "acalabrutinib-venetoclax with or without obinutuzumab demonstrated prolonged PFS vs chemoimmunotherapy (investigator's choice of fludarabine, cyclophosphamide, and rituximab [FCR] or BR) in patients with treatment-naive CLL without del(17p) or TP53 mutations."